Albert P Li
Li A, Doshi U. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4. Drug Metab Lett. 2011;5:183-91 pubmed
..The higher throughput assays describe here can to be used routinely for the evaluation of time-dependent CYP3A4 inhibitory potential of drug candidates during early phases of drug development. ..
Li A. In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development. Curr Top Med Chem. 2014;14:1325-38 pubmed
..The use of the novel integrated discrete multiple organ coculture (IdMOC) system allows the evaluation of the role of hepatic metabolism on nonhepatic toxicity. ..
Li A, Yang Q, Vermet H, Raoust N, Klieber S, Fabre G. Evaluation of human hepatocytes under prolonged culture in a novel medium for the maintenance of hepatic differentiation: results with the model pro-inflammatory cytokine interleukin 6. Drug Metab Lett. 2014;8:12-8 pubmed
..1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4. The results suggest that the LS-human hepatocytes may represent a physiologically relevant experimental model for mechanistic investigation of the down-regulatory effects of inflammatory cytokines. ..
Peng C, Doshi U, Prakash C, Li A. A Novel Plated Hepatocyte Relay Assay (PHRA) for In Vitro Evaluation of Hepatic Metabolic Clearance of Slowly Metabolized Compounds. Drug Metab Lett. 2016;10:3-15 pubmed
..PHRA represents a useful experimental system for the evaluation of the metabolic fates of low clearance compounds in drug development. ..
Li A, Alam N, Amaral K, Ho M, Loretz C, Mitchell W, et al
. Cryopreserved Human Intestinal Mucosal Epithelium: A Novel In Vitro Experimental System for the Evaluation of Enteric Drug Metabolism, Cytochrome P450 Induction, and Enterotoxicity. Drug Metab Dispos. 2018;46:1562-1571 pubmed publisher
..These results suggest that CHIM may be a useful in vitro experimental model for the evaluation of enteric drug properties, including drug metabolism, drug-drug interactions, and drug toxicity. ..
Zhang J, Doshi U, Suzuki A, Chang C, Borlak J, Li A, et al
. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact. 2016;255:3-11 pubmed publisher
..0001). The results suggest that evaluation of drugs in primary human hepatocytes using the ROS/ATP ratio endpoint may aid the definition of their potential to cause severe DILI. ..
Utkarsh D, Loretz C, Li A. InÂ vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries. Chem Biol Interact. 2016;255:12-22 pubmed publisher
..Our results with primary cultured hepatocytes from multiple donors support the hypothesis that elevated P450 activity may be a risk factor for drug-induced liver injuries. ..
Li A, Ho M, Amaral K, Loretz C. A Novel In Vitro Experimental System for the Evaluation of Drug Metabolism: Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Cryopreserved Human Hepatocytes). Drug Metab Dispos. 2018;46:1608-1616 pubmed publisher
..Our results suggest that the MMHHs system represents a convenient and robust in vitro experimental system for the evaluation of drug metabolism. ..
Li A. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos. 2009;37:1598-603 pubmed publisher